La vendita allo scoperto per Tidal ETF Trust II YieldMax XOM Option Income Strategy ETF dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Tidal ETF Trust II YieldMax XOM Option Income Strategy ETF. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Tidal ETF Trust II YieldMax XOM Option Income Strategy ETF (ARCA:XOMO), Report sulle vendite allo scoperto

The Fund is an actively managed exchange-traded fund (ETF) that seeks current income while maintaining the opportunity for exposure to the share price (i.e., the price returns) of the common stock of Exxon Mobil Corporation (XOM), subject to a limit on potential investment gains. The Fund will seek to employ its investment strategy as it relates to XOM regardless of whether there are periods of adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods.

First American Government Obligations Fund

YieldMax XOM Option Income Strategy ETF

Tidal ETF Trust II YieldMax XOM Option Income Strategy ETF

Telsey Advisory Group analyst Cristina Fernandez maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Outperform and maintains $255 price target.

News

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on RH, Maintains $255 Price Target

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) with a Buy and maintains $35 price target.

Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $35 Price Target

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1)
 &nbsp;

Merck & Company Says FDA Has Approved KEYTRUDA (pembrolizumab) For PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma As Neoadjuvant Treatment, Continued As Adjuvant Treatment Combined With Radiotherapy With Or Without Cisplatin Then As A Single Agent

Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>), a clinical-stage diabetes and obesity medicines company, today announced updated preliminary clinical data from the ongoing Phase I COVALENT-103 trial of BMF-500 in adults with relapsed or refractory ("R/R") acute leukemia ("AL"). The results will be presented in a poster presentation at the European Hematology Association ("EHA") 2025 Congress in Milan, Italy.
The presentation by Dr. Farhad Ravandi of The University of Texas MD Anderson Cancer Center will highlight emerging safety, pharmacokinetics/pharmacodynamics, and early clinical activity data for BMF-500, a highly selective covalent FMS-like tyrosine kinase 3 ("FLT3") inhibitor, in heavily pretreated patients with R/R AL.
Key Results from the EHA 2025 Poster Presentation 27 patients were enrolled across two study arms, Arm A (no CYP3A4 inhibitor; n=10) and Arm B (CYP3A4 inhibitor; n=17). All patients had R/R AL, with a median of 4 prior lines of therapy. 18 of the 27 patients were FLT3 mutations ("FLT3m") while the other 9 patients had FLT3 wild-type AL. Frequent co-mutations included WT1, TP53, IDH1/2, and NRAS. All 18 FLT3m patients had failed gilteritinib in the R/R setting and 9 of the 18 had received at least two FLT3 inhibitors prior to study entry. 26 of 27 (96%) enrolled patients had also received and failed the BCL2 inhibitor venetoclax. Key findings include:
Clinical Activity Observed:
<ul>
<li>9 of 11 efficacy-evaluable FLT3m patients, defined as all patients enrolled who received at least one dose and had at least one disease assessment, showed bone marrow (BM) blast reduction; 5 of 11 achieved &gt;50% BM blast reduction.</li>
<li>1 FLT3m patient achieved complete remission with incomplete hematologic recovery (CRi), sustained for 6 cycles.</li>
<li>1 FLT3m patient achieved morphologic leukemia-free state (MLFS); response is ongoing.</li>
<li>1 FLT3m patient met all criteria for partial response (PR) except platelet recovery; categorized as near PR.</li>
<li>2 of 4 efficacy-evaluable FLT3 wild-type patients achieved durable disease control ≥120 days, with treatment ongoing for one patient.</li>
<li>Additional clinical improvements include reductions in peripheral blasts, transfusion dependency, and frequency of hydroxyurea use.</li>
</ul>
Pharmacokinetics/Pharmacodynamics:
<ul>
<li>FLT3 inhibition correlated with BMF-500 systemic exposures.</li>
<li>Bone marrow and plasma concentrations of BMF-500 and its metabolites were comparable, suggesting good compartmental penetration.</li>
</ul>
Survival:
<ul>
<li>Median overall survival (mOS) among all treated FLT3m patients (n=18) was 3.8 months (Arm A) and 3.5 months (Arm B) during dose escalation.</li>
<li>For the efficacy-evaluable FLT3m patients (n=12), the mOS for Arms A and B was 3.8 and 3.6 months, respectively during dose escalation.</li>
<li>These survival durations compare favorably to historical mOS of 2.1 months in patients with R/R FLT3m acute myeloid leukemia ("AML") post-failure with both gilteritinib and venetoclax.&nbsp;</li>
</ul>
Ongoing Dose Escalation:
<ul>
<li>Dose escalation continues at 200 mg BID (Arm A) and 75 mg BID (Arm B).</li>
<li>Based on observed activity and tolerability, further evaluation is underway to determine optimal biologic dose ("OBD") and recommended Phase II dose ("RP2D").</li>
</ul>
Safety and Tolerability
<ul>
<li>BMF-500 was generally well-tolerated across dose levels.</li>
<li>No dose-limiting toxicities (DLTs), QT prolongation, or discontinuations due to treatment-related adverse events were reported.</li>
<li>Escalation is ongoing without safety restrictions.</li>
</ul>
Following completion of the COVALENT-103 dose escalation phase in R/R AL patients with FLT3m, Biomea plans to conclude its internal development of BMF-500 in oncology and is actively exploring strategic partnerships to advance the program.

BMEA

Biomea Fusion Presents Updated Preliminary Clinical Data From Ongoing Phase I COVALENT-103 Trial Of BMF-500 In Adults With R/R Acute Leukemia, At EHA 2025 Congress

WIIM

SHEL

Shraes of energy stocks are trading higher following Israel's strikes on Iran, which have raised oil prices amid potential disruptions in production.

Biotech

Large Cap

Health Care

Contracts

General

AstraZeneca Has Entered A Strategic Research Collaboration With Shijiazhuang City-based CSPC Pharmaceuticals For Oral Candidates To Treat Diseases Across Multiple Indications, CSPC Will Receive An Upfront Payment Of $110M, And Is Also Eligible To Receive Up To $1.62B In Potential Development Milestone Payments And Up To $3.6B In Sales Milestone Payments, Plus Potential Single-digit Sales Based Royalties.

JBLU

Shares of airline stocks are trading lower following Israel's strikes on Iran, which have raised fuel prices and could cloud the travel demand outlook. The recent crash of an Air India flight could also be pressuring the sector.

GPUS

Hyperscale Data Projects $41M Annual Bitcoin Mining Run Rate Starting July 2025 With 19,200 Miners Across US Sites

BITF

CLSK

COIN

HIVE

MARA

MSTR

RIOT

Shares of crypto-linked stocks are trading lower following Israel's strikes on Iran, as risk-off sentiment pressures speculative assets.

$BTC

Bitcoin is trading lower following Israel's strikes on Iran, as the attacks could weigh on risk sentiment.

Shares of defense stocks are trading higher following Israel's strikes on Iran, which could lift demand outlook for military equipment.

Gold and silver are trading higher following Israel's attack on Iran, which has caused macro uncertainty and raised demand for safe-haven assets.

SPHL

Springview Singapore Says It Earns bizSAFE Level 4 Certification, Boosting Safety Standards And Market Opportunities

Oil is trading higher following Israel's strikes on Iran, which have caused supply uncertainty.

Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock. In addition, Enliven intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of its common stock. All of the shares of common stock and pre-funded warrants are being offered by Enliven. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

ELVN

Enliven Therapeutics Launches $200M Public Offering With Option For $30M Upsize

Shares of defense stocks Rtx Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) and General Dynamics Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) climbed 4.6%, 4.2% and 1.2%, respectively, during Friday&#8217;s pre-market trading session amid Israel&#8217;s intensifying military <a href="https://www.benzinga.com/markets/equities/25/06/45921212/us-stocks-likely-to-open-lower-as-israel-strikes-iran-geopolitical-risks-offers-upside-for-dollar-say-experts">operations in Lebanon and Iran.</a>
What Happened: Israel recently initiated an invasion of Lebanon and executed <a href="https://www.benzinga.com/news/politics/25/06/45919250/trump-administration-distances-us-from-israels-strikes-on-iran-we-are-not-involved-says-marco-rubio">leaders of Iran&#8217;s IRGC. </a>This act provoked Iran to launch extensive strikes against targets within Israel. Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), the largest arms manufacturer globally, produces the F-35 aircraft, which Israel employs in its regular bombardments of Gaza. 
RTX Corporation, formerly Raytheon, the second-largest arms manufacturer, provides Israel with &#8220;bunker buster&#8221; bombs, which are prohibited in densely populated areas.
Meanwhile, General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>), another manufacturer of bunker busters, produces the BLU-109 bombs currently used by Israel.
SEE ALSO:&nbsp;<a href="https://benzinga.com/pressreleases/24/10/ab41310379/claritycheck-launches-innovative-reverse-lookup-tool-to-empower-users-against-digital-scams" target="_blank" rel="noreferrer noopener">ClarityCheck Launches Innovative Reverse Lookup Tool to Empower Users Against Digital Scams &#8211; Benzinga</a>
Why It Matters: The escalating tension in the Middle East has had a profound impact on global markets. Israel&#8217;s preemptive strike on Iran caused U.S. stock <a href="https://www.benzinga.com/markets/market-summary/25/06/45918802/middle-east-tensions-rattle-markets-us-stock-futures-slide-oil-jumps-8-gold-surges-above-3400-after-israel-strikes-iran">futures to slide</a>, oil prices to jump 8%, and gold to surge above $3,400.
Moreover, the Trump administration has distanced itself from Israel&#8217;s recent <a href="https://www.benzinga.com/news/politics/25/06/45919250/trump-administration-distances-us-from-israels-strikes-on-iran-we-are-not-involved-says-marco-rubio">military actions </a>against Iran. These strikes are expected to complicate President Donald Trump's efforts to negotiate a nuclear deal with Tehran.
Lastly, President Trump&#8217;s ambitious $175 billion plan <a href="https://www.benzinga.com/25/05/45548110/trumps-golden-dome-launches-new-era-for-defense-stocks-like-rtx-lockheed-martin-l3harris">to develop</a> a &#8220;Golden Dome&#8221; missile defense system announced in May is expected to usher in a new era for defense stocks like RTX, Lockheed Martin, and L3Harris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>).
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/tech/25/06/45897537/jamie-dimon-recalls-first-palantir-meeting-holy-christ-this-is-unbelievable-jpmorgan-now-has-600-ai-" target="_blank" rel="noreferrer noopener">Jamie Dimon Recalls First Palantir Meeting: &#8216;Holy Christ, This Is Unbelievable—&#8217; JPMorgan Now Has 600 AI Use Cases, $2 Billion Annual Investment On AI</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Lockheed Martin, RTX, General Dynamics And Other Defense Stocks Rise In Friday Pre-Market: What's Going On?

Kennedy Wilson Buys 265-Unit Seattle Multifamily Asset For $173M, , Expands Investment Platform With Japanese Partners

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved &nbsp;

Enliven Therapeutics Announced Updated Data From Phase 1 ENABLE Clinical Trial Evaluating ELVN-001 In Patients With Chronic Myeloid Leukemia In An Oral Presentation At European Hematology Association 2025 Congress

Cloudflare Prices $1.75B Convertible Notes Due 2030 With Optional $250M Upsize, Eyes $1.72B Net Proceeds

ZKH Group Limited ("ZKH" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>), a leading maintenance, repair and operations ("MRO") procurement service platform in China, today announced that its board of directors has authorized a new share repurchase program under which the Company may repurchase up to US$50 million worth of its shares (including American Depositary Shares) over the next 12 months, ending on June 13, 2026.
The share repurchases may be effected from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions, and will be implemented in accordance with applicable rules and regulations. The Company expects to fund the repurchases out of its existing cash balance.

ZKH Group Launches $50M Share Buyback Program Through June 2026, Funded From Cash Reserves

Comments

Tidal ETF Trust II YieldMax XOM Option Income Strategy ETF

Vendite allo scoperto

Tidal ETF Trust II YieldMax XOM Option Income Strategy ETF (ARCA:XOMO), Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO